← All medicines

Withdrawn and historical medicines

Umbralisib — withdrawn U.S. approval

Independent educational summary · Sources checked November 20, 2026

Historically used for selected lymphomas. FDA withdrew U.S. approval in 2022 because safety concerns outweighed the demonstrated benefit.

Profile scope: Umbralisib — withdrawn U.S. approval. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Older patient information describes digestive upset, fatigue, swelling, and body discomfort.

Serious risks and warning signs

FDA identified a possible increased risk of death in trial findings. The NIH monograph also describes serious infection, severe diarrhea or bleeding, liver-related symptoms, and severe skin reactions. This is a historical profile, not a current treatment option.

A question for your healthcare team

If this medicine appears in my treatment history, what follow-up or records review should my specialist consider?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.